PT - JOURNAL ARTICLE AU - Maliha Afrin Proma AU - Sohel Daria AU - Salsabil Islam AU - Zabun Nahar AU - Sardar Mohammad Ashraful Islam AU - Mohiuddin Ahmed Bhuiyan AU - Md. Rabiul Islam TI - Monocyte chemoattractant protein-1 levels are associated with major depressive disorder AID - 10.1101/2020.11.26.20239293 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.26.20239293 4099 - http://medrxiv.org/content/early/2020/11/30/2020.11.26.20239293.short 4100 - http://medrxiv.org/content/early/2020/11/30/2020.11.26.20239293.full AB - Major depressive disorder (MDD) is a distressing condition characterized by persistent low mood, loss of interest in daily activities. Many biological, psycho-social, and genetic factors are thought to be involved with depression. The present study aimed to investigate the serum levels of monocyte chemoattractant protein-1 (MCP-1) in MDD patients to explore its role in the development of depression. This case-control study recruited 114 MDD patients and 106 healthy controls (HCs) matched by age and gender. A specialized psychiatrist diagnosed the cases and evaluated the controls based on the diagnostic and statistical manual for mental disorders, 5th edition. The serum MCP-1 levels were quantified by commercially available enzyme-linked immune sorbent assay kits. The Hamilton depression rating scale (Ham-D) was applied to measure the severity of depression. We observed the decreased levels of serum MCP-1 in MDD patients compared to HCs. A significant negative correlation was obtained between serum MCP-1 levels and Ham-D scores. Also, female MDD patients with higher Ham-D scores exhibited lower serum MCP-1 levels. The receiver operating characteristic analysis demonstrated the good diagnostic value of MCP-1 with the area under the curve at 0.837. The depression-related alteration of serum MCP-1 may be more complicated than the current assumption and depends on the characteristics of the individual patients. Our study suggests that the serum MCP-1 levels might be involved in the pathophysiology and mechanism of MDD. The present findings, along with the diagnostic evaluation, might be used to assess the depression risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was self-funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical review committee of the department of psychiatry, BSMMU, reviewed, and approved this study protocol (reference BSMMU/2019/3507). The principles mentioned in the Declaration of Helsinki were strictly followed during performing all the investigations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the present study findings are within this article. All the relevant data and information can be obtained from the corresponding author upon reasonable request.